Healthcare Economy

Best BioHealth Stocks of 2010, Outlook for 2011 (JAZZ, DNDN, HGSI, ARIA, AMRN, NBIX, THRX)

2010 has been an interesting year in biotech and in biohealth stocks, even if it has lacked some of the ten-baggers that were seen in 2009.  In 2009, companies like Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Dendreon Corp. (NASDAQ: DNDN), and Human Genome Sciences, Inc. (NASDAQ: HGSI) led the 2009 pack with exponential returns that were 500% and higher.  At BioHealthInvestor.com, we have tracked many of the exponential winners for 2010 with outlooks into 2011.  Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is our sole repeat performer in 2010.  Others include ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Amarin Corporation plc (NASDAQ: AMRN), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Theravance Inc. (NASDAQ: THRX).

Many companies were screened out because performance has faltered or because of limited history.  Read the full lists below at BioHealthInvestor.com:

 

Stocks covered above in detail at BioHealthInvestor.com are ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), EntreMed Inc. (NASDAQ: ENMD), Exact Sciences Corporation (NASDAQ: EXAS), Exelixis, Inc. (NASDAQ: EXEL), Amicus Therapeutics, Inc. (NASDAQ: FOLD), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Amarin Corporation plc (NASDAQ: AMRN), Illumina Inc. (NASDAQ: ILMN), Inhibitex Inc. (NASDAQ: INHX), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Neurocrine Biosciences Inc. (NASDAQ: NBIX), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM).

You can also see the same sort of search from 2009 for the 2010 outlook that was done at BioHealthInvestor.com.

JON C. OGG